Background: Dendritic cell (DC)-derived indolamine 2,3-dioxygenase (IDO) degrades tryptophan to kynurenine, which promotes conversion of inflammatory T cells in immunosuppressive regulatory T cells (Tregs). We analyzed the significance of the IDO:Treg axis for inducing and maintaining mucosal healing in ulcerative colitis (UC). Methods: Dextran sodium sulphate (DSS)-induced colitis in BALB/c mice (model for mucosal healing) and C57BL/6 mice (model for persistent disease) was used. Serum, fecal samples and colon-infiltrating immune cells of 65 patients with UC with mucosal healing or persistent colitis were analyzed. Results: Significantly higher serum levels of kynurenine and downregulated inflammatory cytokines were noticed in DSS-treated BALB/c mice compared with C57BL/6 mice. Increased IDO activity and attenuated capacity for antigen presentation and production of inflammatory cytokines, observed in BALB/c DCs, was followed by a significantly lower number of inflammatory T helper 1 (Th1) and Th17 cells and a notably increased number of Tregs in the colons of DSS-treated BALB/c mice. DCs and Tregs were crucially important for the maintenance of mucosal healing since their depletion aggravated colitis. Mucosal healing, followed by an increase in kynurenine and intestinal Tregs, was re-established when BALB/c DCs were transferred into DC-depleted or Treg-depleted DSS-treated BALB/c mice. This phenomenon was completely abrogated by the IDO inhibitor. Significantly higher serum and fecal levels of kynurenine, accompanied by an increased presence of intestinal Tregs, were noticed in patients with UC with mucosal healing and negatively correlated with disease severity, fecal calprotectin, colon-infiltrating interferon γ and interleukin-17-producing cells, serum and fecal levels of inflammatory cytokines. Conclusion: IDO-dependent expansion of endogenous Tregs should be further explored as a new approach for the induction and maintenance of mucosal healing in patients with UC.
Introduction
Ulcerative colitis (UC) is a chronic, idiopathic and relapsing inflammatory disease of the gut limited to the mucosal layer of the colon and rectum. 1 Accordingly, mucosal healing, defined as the absence of friability, blood, erosions and ulcers in all visualized segments of the gut mucosa, 2 represents the ultimate therapeutic goal
The importance of tryptophan and its metabolites for the progression of UC has been recently indicated by Nikolaus and colleagues 7 who noticed significantly lower serum levels of tryptophan in patients with UC than in healthy controls. Several recently published animal studies showed that administration of tryptophan or its metabolites led to the attenuation of experimental colitis, whereas removing tryptophan from the diet increases susceptibility to colitis. [8] [9] [10] In the inflammatory microenvironment of the gut, the kynurenin pathway comprises most of tryptophan metabolism. 11 In the presence of inflammatory cytokines, intestinal dendritic cells (DCs) produce indolamine 2,3-dioxygenase (IDO), a hemecontaining enzyme that degrades tryptophan to kynurenine. 12 Gut DCs, in an IDO-dependent manner, promote the conversion of inflammatory T cells into immunosuppressive regulatory T cells (Tregs), enabling induction of immune tolerance in the gut. 12 Dextran sodium sulphate (DSS)-induced colitis has been mostly used to elucidate the molecular and cellular pathways involved in the pathogenesis of UC and for the evaluation of new diagnostic and therapeutic approaches for UC treatment. 13 Interestingly, as it was recently demonstrated by Melgar and colleagues, 14 DSS induces a different degree of colon injury and inflammation when applied to C57BL/6 and BALB/c mice. The acute disease in C57BL/6 mice progresses to a severe, chronic colitis, while acute DSS-induced colitis in BALB/c mice is self limited and starts to resolve immediately after DSS removal. 14, 15 It is supposed that strain-dependent differences in resolution of DSS-induced inflammation reflect the ability of these strains to mount different healing mechanisms. 16 Accordingly, the acute model of DSS-induced colitis in BALB/c mice is useful to study normal mucosal healing while that for DSSinjured C57BL/6 mice offers a promising animal model for the evaluation of pathological inflammatory changes observed in patients with chronic progressive UC. 14 Here, we provide the first evidence that higher IDO activity in BALB/c DCs and the consequent IDO-dependent increase in the total number of colon-infiltrating Tregs are responsible for mucosal healing in DSS-treated BALB/c mice. Similarly, we observed higher serum and fecal levels of kynurenine and an increased presence of colon-infiltrating Tregs in patients with UC and mucosal healing. In contrast, patients with UC that is progressive had lower serum and fecal levels of kynurenine and a reduced number of gut infiltrated Tregs. Taken together, this experimental and clinical data suggest the importance of the IDO:Tregs axis for resolution of colon inflammation and strongly indicate the possible diagnostic and therapeutic potential of kynurenine for achieving and maintaining mucosal healing in patients with UC.
Material and methods

Study population
This study recruited a total of 65 patients with UC (38 male and 27 female) with a median age of 50 years (range . Additionally, 20 healthy subjects (11 male and 9 female) with a median age of 48 years (range 25-75), whose checkups were finished at the Clinical Center of Kragujevac as a routine item, were randomly chosen to represent the general population as healthy controls. Patients with UC were classified into two groups: mucosal healing (19 male and 20 female patients with a median age of 50 years) and chronic persistent disease (19 male and 7 female patients with a median age of 50 years) ( Table 1 ). In each individual case, the diagnosis and assessment of the severity of UC was confirmed by the Mayo endoscopic subscore, histological and clinical scores and by measurement of C-reactive protein (CRP) and fecal calprotectin. 3, [17] [18] [19] [20] All endoscopies were journals.sagepub.com/home/tag 3 performed by the same experienced endoscopist (NZ) and disease severity was independently determined by two gastroenterologists (MJ and NZ). Mucosal healing was defined when Mayo endoscopic subscore had been transitioned from a Mayo grade 2 or 3 to a Mayo grade 0 or 1, while chronic persistent disease was defined when the Mayo endoscopic subscore was 2 or 3. 3 The clinical score was determined by using the Truelove and Witts clinical activity index. 18 The histological score was determined by using Geboes grade. 19 Patients with previously diagnosed colorectal cancer, as well as patients with Crohn's disease, were excluded from the study. The study was conducted at the Center for Gastroenterology, 
Measurements of IDO activity, concentration of cytokines, fecal calprotectin and CRP levels in serum and fecal samples of patients with UC and healthy controls
Blood and fecal samples were prepared as previously described. 21 The serums and supernatant fluids were collected and stored at −80°C until they were measured by enzyme-linked immunosorbent assay (ELISA). IDO activity was determined by spectrophotometric assay for kynurenine in the serum and fecal samples of patients with UC and healthy controls. 22 Tumor necrosis factor (TNF)-α, interleukin (IL)-10, CXCL11 and IL-17, fecal calprotectin and CRP were measured in serum and fecal samples of patients with UC and healthy subjects by using commercially available ELISA tests, according to the manufacturer's instructions. 17 Induction of experimental colitis DSS (3%, molecular weight 40 kDa; TdB Consultancy, Uppsala, Sweden) was given to mice in place of normal drinking water for up to 5 days, followed by a recovery period of 7 days. 24 Control mice had access to DSS-free water.
Evaluation of DSS-induced colitis
Disease Activity Index (DAI) was used to assess the clinical signs of colitis. 25 Body weight measurements, analysis of stool consistency, and fecal occult blood tests were performed daily. 25 For histological analysis, colons were removed from euthanized mice, rinsed with PBS, and cut longitudinally before being rolled into a 'Swiss roll'. 26 The length of each colon was measured starting from the end of the cecum to the rectum. The exact same areas (distal anorectal regions) were analyzed in all samples. The histology scores for each mouse were calculated as the sum of 'damage of epithelium' and 'infiltration' subscores. 
Flow cytometry analysis of colon-infiltrating cells in DSS-treated mice
Isolation of immune cells from lamina propria of experimental animals was conducted as previously described. 29 Each colon was dissected away from the caecum. The colons were cut into pieces 3 cm long and then cut longitudinally, so that 3 × 3 cm flaps of colonic tissue were made. The flaps were placed in a 50 ml conical tube and washed three to five times with 30 ml cold HBSS, calcium and magnesium free. The pieces were incubated in 20 ml HBSS/EDTA for 30 min in a 37°C water bath. Each tube was shaken regularly during the incubation to ensure that epithelial cells were disrupted from the mucosa. The pieces were sedimented and the supernatant was decanted. The remaining EDTA were washed out with 40 ml HBSS, calcium and magnesium free. The fragments of colonic tissue were placed in a 10 cm Petri dish and cut into smaller pieces with a scalpel. The pieces were aspirated with a pipette, transferred to a fresh 50 ml conical tube and filled to 20 ml with DMEM supplemented with 10% FBS. Then, 1 ml of 4000 Mandl units/ml collagenase D (SigmaAldrich) and 200 μl of 1 mg/ml DNase (SigmaAldrich) were added to the tube and incubated for 1 h in a 37°C water bath. The supernatant was filtered through a 100 μm nylon cell strainer into a clean 50 ml conical tube. Cold HBSS, calcium and magnesium free, was added to 50 ml. Cells were pelleted by centrifuging 10 min at 450 g, at 4°C. The pellet was disrupted and cells were resuspended in 50 ml HBSS, calcium and magnesium free, and filtered through a 40 μm nylon cell strainer into a clean 50 ml conical tube. Cells were again pelleted by centrifuging for 10 min at 450 g, at 4°C. The pellet was disrupted and cells were resuspended in 20 ml of 30% Percoll. Afterwards, the cell suspension was layered over 25 ml of 70% Percoll in a 50 ml conical tube and centrifuged for 20 min at 1100 g, room temperature, with as low an acceleration rate as possible and with the brake off. 
Determination of cytokines in serum samples of experimental animals
The commercial ELISA sets (R&D Systems, Minneapolis, MN, USA) were used to determine the concentration of IL-12, IL-1β and IL-10 in serum samples of control and DSS-treated animals. 25 
Isolation of DCs and analysis of their phenotype and function
DCs were isolated from spleens of DSS-treated C57BL/6 and BALBc mice 2 days after administration of DSS by magnetic cell sorting. Single-cell suspensions of mononuclear cells derived from the spleen were labelled with CD11c MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and positively selected using MACS Column and MACS Separator. Isolated DCs were stimulated with lipopolysaccharides (LPS, 10 ng/ml) for 48 h, harvested and analyzed by flow cytometry. 25 
Determination of IDO activity in DCs
Expression of IDO in DCs was determined by real-time polymerase chain reaction (PCR). The fold change of mRNA gene expression for IDO and β actin, used as a housekeeping gene (Invitrogen, Carlsbad, CA, USA), was calculated. 30 IDO activity was determined by spectrophotometric measurement of kynurenine in the supernatants of LPS (10 ng/ml) stimulated spleen DCs previously isolated from untreated or DSStreated mice, 2 days after DSS administration. 22 
Depletion of DCs and adoptive transfer of DCs in DC-depleted DSS-treated mice
Since gut CD103+ DCs express IDO responsible for expansion of colon-infiltrating Tregs, 12 these DCs were selectively depleted in DSS-treated BALB/c mice by using immunotoxin-saporin capable of selectively depleting DCs (Advanced 6 journals.sagepub.com/home/tag
Targeting Systems, San Diego, CA, USA). 31 Since this immunotoxin significantly reduces the frequencies and absolute numbers of DCs within 1 week of treatment, 31 DSS-treated BALB/c mice were, at day 5, injected with saporin (2 mg/kg, intraperitoneally) while clinical and histological manifestation of DC depletion were analyzed 1 week later.
IDO activity was inhibited in BALB/c DCs (DCs 1-MT ) by culturing DCs, previously isolated from healthy BALB/c mice, in culture medium containing 1 mM 1-MT. 32 Immunotoxin-saporin used for depletion of DCs is cleared from the circulation by day 3 post injection. 31 Accordingly, for adoptive transfer experiments, DCs with normal or suppressed IDO activity (DCs 1-MT ), previously isolated from healthy BALB/c mice, were transferred (intraperitoneally; 2 × 10 5 DCs/ mouse) into DC-depleted DSS-treated BALB/c mice 72 h after saporin injection.
Depletion of Treg cells and adoptive transfer of DCs in Treg-depleted DSS-treated mice
For Treg depletion, mice were injected intraperitoneally with cyclophosphamide (CY, Galenika A.D., Belgrade, Serbia) at a dose of 10 mg/kg or anti-CD25 antibody (PC61 mAb, Sigma-Aldrich, Munich, Germany), at a dose of 250 mg/mouse, 3 days before DSS administration. 33, 34 For adoptive transfer experiments, isolated DCs (2 × 10 5 cells per mouse) were transferred intraperitoneally into CY+DSS-treated and anti-CD25-antibody-treated BALB/c mice at day 5. 35 
Statistical analysis
Data were expressed as the mean ± standard error of the mean (SEM). Results were analyzed by Student's t test, Pearson's or Spearman's correlation coefficient and SPSS 22.0 for Windows software (SPSS Inc., Chicago, IL, USA). The difference was considered significant when p was less than 0.05.
Results
Serum concentration of kynurenine reflected the strain-dependent difference in mucosal healing of DSS-treated C57Bl/6 and BALB/c mice
As previously reported by Melgar and colleagues, 14 Importantly, the serum concentration of kynurenine reflected the strain-dependent difference in mucosal healing. Significantly higher serum levels of kynurenine were noticed in DSS-treated BALB/c mice that recover faster from DSSinduced colon injury than C57Bl/6 mice [p < 0.05; Figure 1 (G)].
To investigate whether a difference in serum concentration of kynurenine was accompanied by a different cytokine profile, concentrations of inflammatory cytokines (IL-12 and IL-1β) and immunosuppressive IL-10 were analyzed in the serum samples of DSS-treated C57BL/6 and BALB/c mice. Serum levels of inflammatory IL-12 and IL-1β were significantly lower [p < 0.05; Figure 1 (H, I)], while the concentration of anti-inflammatory IL-10 was significantly higher in the sera of DSS-treated BALB/c mice compared with DSS-treated C57BL/6 mice , rectal bleeding (C), length of colon (D) and histological score (E) revealed strain-specific difference in recovery from DSS at day 12. Destruction of the entire epithelium, decreased number of goblet cells and loss of crypts, accompanied by severe submucosal edema and massive infiltration of inflammatory cells in the lamina propria and submucosa were observed in the colons of C57BL/6 DSS-treated mice (Fb, 10×/100×). In contrast, distal colon sections of DSS-treated BALB/c mice revealed almost normal architecture of the colon, minimal changes in the surface epithelium and mild infiltration of inflammatory cells to the mucosa (Fd, 10×/100×). Significantly higher serum levels of kynurenine were noticed in DSS-treated BALB/c mice (G). Serum levels of inflammatory interleukin (IL)-12 (H) and IL-1β (I) were significantly lower (p < 0.05), while the concentration of antiinflammatory IL-10 (J) was significantly higher in the sera of DSS-treated BALB/c mice compared with DSS-treated C57BL/6 mice. Data presented as mean ± standard error of the mean; n = 10/group. *p < 0.05, **p < 0.01. were noticed in the lamina propria of DSStreated BALB/c mice compared with DSStreated C57BL/6 mice, confirming the importance of strain-dependent differences for phenotype and function of colon-infiltrating DCs. Similar to that observed in DSS-susceptible C57BL/6 mice (Da, 10×/100×), notable mucosal damage and epithelial necrosis, focal crypt lesions, goblet cell loss and inflammatory cell infiltration were noticed in the colons of CY+DSS-treated (Dc, 10×/100×) and anti-CD25+DSS-treated BALB/c mice (De, 10×/100×). These pathological changes in colon architecture were manifested by a significant increase in the histological score of CY+DSS-treated and anti-CD25+DSS-treated BALB/c mice (C). A significant increase in the serum levels of interleukin (IL)-12 (E), a decrease in the serum levels of IL-10 (F) and a significantly lower number of coloninfiltrating Tregs (H) were noticed in CY+DSS-treated and anti-CD25+DSS-treated BALB/c mice. Adaptive transfer of BALB/c DCs significantly attenuated DAI (B), histological score (C), colon injury and inflammation (Dd, Df), the serum levels of IL-12 (E) and significantly increased the serum concentrations of IL-10 (F) and kynurenine (G) as well as the total number of colon-infiltrating CD45+CD4+FoxP3+ Tregs (H) in CY+DSS-treated BALB/c mice that received DCs as well as in anti-CD25+DSS-treated BALB/c animals that were injected with DCs. Mean ± standard error of the mean; n = 10/group. *p < 0.05; **p < 0.01. 
Recovery from DSS-induced colitis of BALB/c mice was a consequence of DCdriven polarization of T cells towards immunosuppressive Tregs
IDO inhibition completely abrogated Tregdependent recovery from DSS-induced colitis in BALB/c mice
DCs, in IDO-dependent manner, promoted expansion of immunosuppressive Tregs enabling mucosal healing in DSS-treated BALB/c mice
To confirm that activity of IDO in DCs is mainly responsible for kynurenine-dependent expansion of immunosuppressive Tregs and consequent maintenance of mucosal healing in DSS-treated BALB/c mice, DCs with normal or suppressed IDO activity (DCs 1-MT ) were transferred into DSS-treated BALB/c animals that were previously depleted of DCs ( Figure 5 ). DSS-induced colitis in BALB/c mice was shown to be significantly more severe when DCs were selectively depleted, manifested by an increased 
Increased serum and fecal levels of kynurenine are noticed in patients with UC and mucosal healing
To investigate the relevance of experimental findings for corresponding human pathology, we analyzed the concentration of kynurenine in serum and stool samples of healthy controls and patients with UC who were divided into two groups based on the presence or absence of mucosal healing (Table 1 ). The serum level of kynurenine was higher in patients with UC compared with healthy controls [ Figure 6 (A)]. Interestingly, significantly higher serum levels of kynurenine were observed in patients with UC and mucosal healing than in patients with UC and chronic persistent disease [p < 0.05; Figure  6 
Discussion
In this paper, by using an experimental model and clinical data, we demonstrated that measurement of serum and fecal levels of kynurenine could be used as a new diagnostic approach that can complement endoscopy, CRP and fecal calprotectin for monitoring or predicting mucosal healing in patients with UC. Additionally, our results indicate the therapeutic potential of IDOdependent expansion of endogenous Tregs as a possible new therapeutic approach for the induction of mucosal healing in patients with UC.
Diverse IDO activity manifested by different serum levels of kynurenine in DSS-treated BALB/c and C57BL/6 mice [ Figure 1 (G)], which were used as animal models for mucosal healing or chronic, persistent colitis, 14 indicated the importance of the IDO and kynurenine pathway for mucosal healing in UC. As shown in Figure 4 , in vivo IDO inhibition completely abrogated mucosal healing in DSS-treated BALB/c mice. Opposite to our findings are the recently published results by Shon and colleagues, 38 who investigated acute DSS-induced colitis in IDOdeficient mice on a C57BL/6 background. They reported that genetic deletion of IDO protected against DSS-induced colitis. We believe that strain-dependent differences in DSS-induced colitis between C57BL/6 and BALB/c mice 14 might be responsible for the contrasting results obtained by us and Shon and colleagues. Additionally, Shon and coworkers investigated the impact of IDO deficiency on acute DSSinduced colitis, which is a T-cell-independent disease, 39 while we evaluated the effects of IDO inhibition 12 days after DSS administration when T cells play an important role in the pathogenesis of colitis. 40 Similar to our results, several experimental studies demonstrated that inhibition of IDO activity worsens colitis while induction of IDO expression limits disease progression, 12, [41] [42] [43] indicating the importance of IDO activity in attenuation of colon inflammation. In line with these findings, we assume that striking differences in clinical and histological manifestations of DSS colitis in C57BL/6 mice with persistent disease and BALB/c mice with mucosal healing were consequences of IDO-and kynurenine-dependent effects on colon-infiltrating Tregs.
Similar to that observed in animal models, serum and fecal levels of kynurenine were increased in patients with UC and mucosal healing, and both negatively correlated with disease severity, serum levels of CRP and concentration of fecal calprotectin ( Figure 6 ). These findings indicate that measurement of kynurenine in the serum and fecal samples of patients with UC could be used as a new diagnostic approach for the prediction or monitoring of mucosal healing in patients with UC.
Currently, measurement of fecal calprotectin is the most commonly used stool-based test for assessing higher in patients with UC and mucosal healing compared with patients with UC and chronic persistent disease (A). Clinical score (B) and histological score (D) were significantly lower in patients with mucosal healing. Clinical score negatively correlated with serum concentrations of kynurenine (C). Mucosal healing was manifested by resolution of acute inflammation, regeneration of epithelium and disappearance of crypt abscesses in the colon (Ea, 100×). By contrast, chronic persistent disease was manifested by the presence of large abscesses and increased infiltration of inflammatory cells in the injured colons (Eb, 100×). The endoscopic subscore was significantly lower in patients with UC and mucosal healing (F). On endoscopy, chronic persistent disease was manifested by marked erythema, friability, erosions and absent vascular patterns (Gb), while all endoscopic parameters were in remission in patients with UC and mucosal healing (Ga). Significantly lower serum levels of inflammatory mediators, C-reactive protein (CRP) (H), tumor necrosis factor (TNF)-α (I) and CXCL11 (J) were noticed in patients with UC and mucosal healing. The concentration of kynurenine in stool samples was significantly higher in patients with UC compared with healthy controls (K). Also, the concentration of kynurenine in stool samples was significantly higher in patients with UC and mucosal healing compared with patients with UC and chronic persistent disease (K) and it corresponded with significantly lower stool levels of fecal calprotectin (L), TNF-α (M), interleukin (IL)-17 (N) and CXCL11 (O). Mean ± standard error of the mean; *p < 0.05; **p < 0.01. progression of UC. 44 Reduction in the concentration of fecal calprotectin represents the most reliable predictor of mucosal healing in patients with UC. 45 Nevertheless, the fecal calprotectin test lacks a validated cutoff, optimal specificity and accuracy, indicating the need for other stool-based biomarkers to complement fecal calprotectin in monitoring mucosal healing. 44 Correlation between increased fecal levels of kynurenine [ Figure 6 (K)] and decreased concentration of fecal calprotectin [ Figure 6 (L)] noticed in patients with UC and mucosal healing indicates that measurement of kynurenine in the fecal samples of patients with UC could become a useful diagnostic tool that can complement fecal calprotectin in monitoring or predicting mucosal healing.
In the inflammatory microenvironment of the gut, the balance between pro-and anti-inflammatory cytokines regulates progression of UC towards mucosal healing or chronic inflammation. 46 Upregulation of DC-derived inflammatory cytokines (IL-1β and IL-12) in injured colons and their elevated concentration in serum samples follow the development of chronic colitis in C57BL/6 mice, while increased serum levels of immunosuppressive IL-10 is accompanied by restoration of the mucosal barrier in BALB/c mice. 14 In line with these findings, BALB/c DCs, compared with C57BL/6 DCs, had reduced capacity for antigen presentation [ Similar to that observed in DSS-induced colitis, an increased concentration of kynurenine in the serum and fecal samples of patients with UC and mucosal healing was accompanied by decreased serum and fecal levels of inflammatory cytokines and elevation of anti-inflammatory IL-10 ( Figure  6 ). In human pathology, among inflammatory cytokines, TNF-α and IL-17 are the most important for progression of UC towards chronic inflammation. 1, 47 Reduction of serum levels of TNF-α predicts long-term remission of UC 48 and the use of anti-TNF-α biological agents represents the most effective therapeutic approach for inducing mucosal healing in patients with UC. 49 Accordingly, downregulation of serum and fecal levels of TNF-α, followed by decreased levels of IL-17, are associated with achievement of mucosal healing in patients with UC who receive anti-TNF-α biologics. 50 Additionally, elevated serum and fecal levels of TNF-α and IL-17 in patients with UC are always accompanied by increased production of CXCL11, which is important for recruitment of activated IFN-γ-and IL-17-producing T lymphocytes and NK cells in the inflamed gut. 51, 52 Through the production of IFN-γ, gut-infiltrated T cells induce activation of IDO, resulting in the conversion of tryptophan in kynurenine that, in turn, increases expression of the IL-10 receptor on intestinal epithelial cells, enabling IL-10-dependent mucosal healing 53 mediated by IL-10-producing T cells which rapidly migrate to the injured colons where they attenuate Th1-and Th17-driven inflammation. 54 Accordingly, induction of mucosal healing is manifested by downregulation of CXCL11, reduced influx of inflammatory cells and increased presence of IL-10-producing anti-inflammatory T and NK cells in the injured colons. 52 In line with these findings, increased serum and fecal levels of kynurenine, observed in patients with UC and mucosal healing [ Figure 6 Tregs accumulate in the injured colons of DSStreated mice and are present at increased density in the colon samples of patients with UC, where, through the production of immunosuppressive IL-10, they suppress IFN-γ-producing Th1 and IL-17-producing Th17 cells, resolving ongoing inflammation. 54 Here, we have demonstrated that Tregs are crucially important for the maintenance of mucosal healing and recovery of BALB/c mice from DSS-induced colitis, since their depletion led to the significant aggravation of colitis ( Figure  3 ). Importantly, adoptive transfer of BALB/c DCs managed to increase the serum levels of kynurenine [ Figure Interestingly, several studies have shown that immunosuppressive Tregs are present in significantly higher numbers in the intestines of patients with UC than in healthy subjects. [56] [57] [58] Our findings are in line with these results [ Figure 6 (A)], as are data obtained by Nikolaus and colleagues, 7 who noticed elevated serum levels of kynurenine in patients with UC compared with healthy controls. It is well known that immunosuppressive Tregs represent a great fraction of lamina propria CD4+ T cells in the colons of patients with UC and that their number is increased during the remission of disease. 57 In line with these findings were significantly increased serum and fecal levels of kynurenine [ Figure 6 (A, K)], followed by an increased presence of colon-infiltrating Tregs [ Figure 7 (C)] that we noticed in patients with UC and mucosal healing compared with patients with UC and chronic persistent disease. This confirms the importance of the IDO/kynurenine pathway for the expansion of endogenous Tregs during mucosal healing. Since the clinical application of Tregs in patients with UC is not easy to perform given their rarity in peripheral blood, 58 IDO-dependent expansion of endogenous Tregs should be further explored as a potentially new approach for the induction and maintenance of mucosal healing in patients with UC. Since colon epithelial cells exhibit an IDO-activity-dependent proliferation phenotype, careful monitoring will be important in clinical trials which are going to investigate the therapeutic potential of agents that will induce IDO expression in patients with UC. 59 
